Eribulin in HER2 Negative Metastatic BrCa

This study is currently recruiting participants.
Verified October 2013 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01827787
First received: April 3, 2013
Last updated: October 31, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)